{"entity":{"id":"nct06761027","kind":"trial","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of anlotinib and sintilimab in pancreatic cancer, run by Fujian Provincial Hospital, now recruiting.","summary":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06761027 by Fujian Provincial Hospital, with a registry enrolment figure of 29 participants, started 2024-12-23 and due to reach its primary completion in 2027-03. Interventions recorded: Anlotinib combined with Sintilimab. Conditions listed: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer. Primary outcome: Objective response rate, ORR. Pancreatic eligibility wording from the registry: \"Patients with locally advanced or metastatic pancreatic cancer diagnosed by histology or cytology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06761027","url":"https://clinicaltrials.gov/study/NCT06761027"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["anlotinib","sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06761027","phase":"1/2","setting":"mFOLFIRINOX Combined With Anlotinib and Sintilimab as First-Line Therapy for Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-arm, Multicenter, Phase Ib/II Clinical Study","sponsor":"Fujian Provincial Hospital","participation":[{"nct":"NCT06761027","source":"https://clinicaltrials.gov/study/NCT06761027","fetchedAt":"2026-10-07T16:55:00.061Z","studySha256":"905d6f158c38ad4b761e43aaa2c9d9b6c8d30714dcb9632f4585b4639a469879","overallStatus":"RECRUITING","lastUpdatePosted":"2025-01-07","leadSponsor":"Fujian Provincial Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":29,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-12-23","startedType":"actual","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06761027/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}